Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2022-07-13 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2022. It is issued by the Registrar and Share Transfer Agent and confirms dematerialization and securities handling compliance. The document is addressed to stock exchanges and is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion but is a regulatory compliance certificate. The document length is short (2774 characters) and it is a certificate under a specific SEBI regulation, which fits the definition of a Regulatory Filing (RNS) rather than a full report or announcement.
2022-07-13 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the closure of the trading window for insiders due to upcoming unaudited financial results for the quarter ended June 30, 2022. It references the regulatory framework for insider trading and specifies the trading window closure period. The document does not contain any financial data, results, or detailed report content. It is an announcement related to compliance and trading restrictions rather than a financial report or earnings release. Given the short length (1531 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2022-06-30 English
Disclosure under SEBI Takeover Regulations
Director's Dealing Classification · 100% confidence The document contains detailed information about share transactions, including dates, number of shares acquired or disposed, percentage of total equity share capital, names of promoters or persons in promoter group, and regulation types. This matches the typical content of a Director's Dealing report, which reports personal share transactions by company directors and executives. The document is short (1294 characters) and focuses solely on share transactions, not on broader financial results or announcements. Therefore, it fits best under the category 'Director's Dealing' (DIRS).
2022-06-18 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about the resignation of a company director, Mr. Mithun Mohan Jadhav. It references compliance with SEBI regulations regarding disclosure of changes in directorship. The content focuses on the resignation event, reasons, and regulatory compliance details. There are no financial statements, earnings data, or report attachments. This fits the category of announcements related to changes in the company's board or senior management, which corresponds to 'Board/Management Information (MANG)'. The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2022-06-17 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Lasa Supergenerics Limited has secured a bulk order of ₹ 500 million. It is addressed to stock exchanges and includes a statement from the Chairman & Managing Director commenting on the order. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a company announcement about a significant business development (bulk order secured), which relates to company operations and growth prospects but does not constitute a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Capital/Financing Update (CAP) as it relates to a significant business order that impacts company revenue and financial outlook, which is typical for such updates.
2022-04-26 English
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the year ended March 31, 2022, submitted pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. It details transactions between the company and its directors, key management personnel, and related parties, including remuneration, sitting fees, loans, commissions, and donations. This type of disclosure is a regulatory filing required by stock exchanges to ensure transparency of related party transactions. It is not an annual report, audit report, earnings release, or any other financial report but a specific regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS). The document length (7955 characters) and content confirm it is a full disclosure, not just an announcement or certification.
2022-04-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.